Preloader

FoundationOne® Heme

Decoding the Tumor to Guide Treatment Decisions

FoundationOne® Heme is an advanced DNA and RNA based comprehensive genomic profiling test that enables detailed molecular characterization of hematologic malignancies. When evaluated together with the lymphoma solution of Signatera™, this integrated approach provides comprehensive support across the oncology care continuum, from molecular diagnosis and treatment selection to post-treatment minimal residual disease (MRD) monitoring.

Technical Specifications
Method:
NGS – Hybrid Capture

Coverage:
DNA + RNA

Intended Use:
Hematologic malignancies and solid tumors
Gene Coverage:
406 DNA genes + 265 RNA genes
Sequencing Depth:
~500×
Variant Types Detected:
SNVs, Indels, CNVs, Fusions, and Gene Rearrangements
Genomic Signatures:
TMB (Tumor Mutational Burden), MSI (Microsatellite Instability)
Translocation Detection:
High-sensitivity DNA and RNA based detection
Sample Types:
FFPE tissue, Peripheral Blood, Bone Marrow
Turnaround Time:
Approximately 14–21 days
Reporting:
Clinically significant variants with Variant Allele Frequency (VAF %) reporting
Additional Features:
• Supports identification of targeted therapy options and prognostic assessment
• Provides insights to support immunotherapy response prediction
//
Our customer support team is here to answer your questions!